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Abstract. Renal cell carcinoma (RCC) may metastasize to 
mediastinal lymph nodes without any abdominal lymph node 
involvement. The present study describes an autopsy-proven 
case of RCC presenting with a large mediastinal mass; the case 
had been previously misdiagnosed as small cell lung carci-
noma due to imaging analysis results, an elevated serum level 
of neuron‑specific enolase and the presence of small atypical 
cells with a high nuclear/cytoplasmic ratio. Despite RCC 
occurrence being rare, it should be considered in the differen-
tial diagnosis, particularly when a mass located in the kidneys 
presents with metastases to the mediastinal lymph nodes, even 
if there is no involvement of the abdominal lymph nodes and 
the primary lesion is of a small size.
Introduction
Renal cell carcinoma (RCC) accounts for 95% of renal neoplasms 
and ~3% of adult malignancies (1). In the United States, 
~61,560 patients with RCC were identified and 14,080 patients 
were predicted to have succumbed to the disease in 2015 (2). 
Generally, patients with RCC present with gross hematuria, 
flank pain and a palpable mass; however, these symptoms are 
not always present. RCC is a heterogeneous disease and several 
histological subtypes have been categorized according to the 
2004 World Health Organization (WHO) renal tumor classi-
fication (3). The mortality rate of patients with RCC depends 
on the histological subtype and the clinical stage of the tumor. 
Since RCC has a hemorrhagic tendency, biopsy of the tumor 
is disputed (4). A diagnosis of RCC is provided according to 
the results observed using imaging methodologies, including 
computed tomography (CT), and a diagnosis of RCC is 
confirmed by the surgical removal of the tumor en bloc. The 
present study reports the case of a patient who presented with 
a large, right mediastinal mass appearing to mimic small cell 
lung cancer (SCLC); however, following autopsy examination, 
the diagnosis was confirmed as RCC.
Case report
A 56‑year‑old male presented at the Ryugasaki Saiseikai 
Hospital (Ryugasaki, Japan) in September 2011 with a dry 
cough that had persisted for 3 months. Physical examination 
identified decreased breath sounds at the right hemithorax. 
Laboratory evaluations were undertaken and included 
urinalysis and testing of blood urea nitrogen, creatinine 
and serum calcium concentrations. All laboratory analyses 
were normal, with the exception of an increased concentra-
tion of white blood cells (12,100 cells/µl; normal range, 
3,900‑9,800 cells/µl), C-reactive protein (12.9 mg/dl; normal 
range, 0.0-0.3 mg/dl) and serum neuron-specific enolase 
(NSE; 50.0 ng/ml; normal range, 0.0-16.3 ng/ml). Following 
a CT scan of the chest, a large mass was detected at the right 
mediastinum, extending directly to the heart, with the pres-
ence of pericardial fluid (Fig. 1). Pleural fluid was identified 
in the right hemithorax, but no abnormalities were observed 
in the lungs and the abdominal lymph nodes were not swollen. 
However, a small nodule was detected in the upper pole of the 
right kidney. A bronchoscopy was performed and a mass was 
identified in the right middle lobe bronchus. A specimen of 
the lesion was taken for cytological examination. Analysis of 
the lesion demonstrated the presence of small atypical cells 
with a high nuclear/cytoplasmic (N/C) ratio; the mass was 
subsequently diagnosed as SCLC. Additionally, the patient 
presented with a metastatic lesion in the brain, and it was 
evaluated as an extension of the disease. The clinical condition 
of the patient rapidly deteriorated, leading to the initiation of 
carboplatin-containing chemotherapy (one course of carbo-
platin, area under the curve=5, every day for 28 days; one 
course of etoposide, 100 mg/m2, every day for 28 days) subse-
quent to the bronchoscopy. Tentative pleural fluid of the right 
hemithorax decreased in response to chemotherapy, however, 
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the respiratory condition of the patient declined. Following 
two courses of chemotherapy, a routine evaluation observed 
enlargement of the mediastinal and renal masses. Further-
more, CT (LightSpeed VCT 64; GE Healthcare Healthcare 
Bio‑Sciences, Pittsburgh, PA, USA) identified a novel lesion 
located in the head of the pancreas. The patient succumbed to 
the disease shortly after the performance of CT.
Autopsy examination demonstrated a large right mediastinal 
lymph node metastasis invading the right lung, the ipsilateral 
mediastinum, the pericardium and the heart. However, no 
association with the abdominal lymph nodes was observed. 
Despite no tumor thrombus being identified in the renal vein 
and inferior vena cava, two tumors in the right kidney were 
detected; one measured 63x55x50 mm in diameter and was 
located in the upper pole of the kidney, and the second tumor 
measured 20x20x18 mm in diameter and was located in the 
lower pole of the kidney (Fig. 2). Microscopically, the two 
tumors were established as the clear cell RCC subtype, although 
cell-cell adhesion was loose in the lower tumor of the kidney 
(Fig. 3). Immunohistochemical staining was performed using 
the following antibodies at a 1:100 dilution: Rabbit monoclonal 
anti‑human cluster of differentiation (CD)10 (cat no. M3670), 
mouse monoclonal anti-human CD15 (cat no. cd15-250), rabbit 
monoclonal anti‑human vimentin (cat no. OPPA01225) and 
mouse monoclonal anti‑human CD7 (cat no. ABIN1384047), 
which were all purchased from Funakoshi, Co., Ltd. (Tokyo, 
Japan). Immunohistochemical staining was observed to be posi-
tive for CD10, CD15 and vimentin, and was negative for CD7. 
The same cancer cells were identified in the metastatic tumors in 
the pancreas head, the mediastinum and the hilar lymph nodes. 
Written informed patient consent was obtained from the 
family of the patient for the publication of this study.
Discussion
RCC is a heterogeneous disease and 12 distinct histological 
subtypes have been categorized in the 2004 WHO classification 
of renal cell tumors (3). Clear cell RCC accounts for ~75% of 
renal cell tumors; the other subtypes are typically summarized 
under the term non-clear cell RCC (5,6). RCC typically develops 
during adulthood, affecting individuals >40 years of age, with 
the incidence peaking during the sixth and seventh decades of 
life. The classic triad of symptoms consists of gross hematuria, 
flank pain and a palpable mass (7). RCC generally presents with 
one or more of these features. A key prognostic factor is the 
clinical stage of the disease at the time of diagnosis. Metastatic 
RCC is present in 20-30% of patients at diagnosis, with the 
majority of these demonstrating multiple metastatic sites (8,9). 
It has been established that RCC can invade the renal vein and 
extend to the inferior vena cava. Furthermore, RCC metasta-
sizes through hematogenous and lymphogenous techniques, and 
Figure 1. Computed tomography scan demonstrating a large mass located at 
the right mediastinum, extending directly to the heart, with the presence of 
pericardial fluid.
Figure 2. Autopsy examination identified two tumors in the right kidney; 
one measured 20x20x18 mm in diameter and was located in the lower pole 
of the kidney (left of image), and the second tumor measured 63x55x50 mm 
in diameter and was located in the upper pole of the kidney (right of image).
Figure 3. Microscopic examination of two kidney tumors. (A) A tumor 
located at the upper pole and (B) a tumor at the lower pole of the right 
kidney. Each was confirmed as clear cell RCC, although cell‑cell adhesion 
was loose in the lower tumor of the kidney. Hematoxylin and eosin staining; 
magnification, x200.
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may also metastasize through the Batson paravertebral venous 
plexus, which communicates with the azygos or hemiazygos 
veins (10,11). The lungs, bones, liver, lymph nodes and medias-
tinum are frequent metastatic sites (12). Among these, the lungs 
are understood to be the most common site of metastasis, with 
pleural dissemination also reported (13). Koç et al (14) described 
the case of a 14‑year‑old male who presented with clear cell 
RCC, which had metastasized to the mediastinal lymph nodes; 
a large mediastinal metastatic mass, without any association 
with the abdominal lymph nodes, was the predominant finding 
of the case, as was similarly observed in the present case. In the 
current study, the key observations were mediastinal lymph node 
metastasis and respiratory distress, which were also observed 
in the case reported by Koç et al (14). In the present case, at 
the time of autopsy, clear cell RCC of the kidney (with tumors 
measuring 60 and 20 mm in diameter) was confirmed, and an 
identical diagnosis was determined for the lesions observed in 
the mediastinal lymph nodes. As there was no evidence of a 
tumor thrombus in the renal vein and inferior vena cava, the 
possibility of hematogenous metastasis appeared to be unlikely.
Several studies have noted elevated serum levels of NSE 
in cases of RCC (15,16), as was observed in the current case. 
NSE is a neuroendocrine marker and is established as a reli-
able tumor marker of SCLC (17). Yaman et al (16) studied 
serum NSE in 25 RCC patients and reported that it may serve 
as a useful marker in the surveillance and evaluation of the 
disease. Rasmuson et al (15) evaluated chromogranin A and 
NSE as neuroendocrine markers in 200 patients with RCC 
and concluded that serum NSE was a significant predictor of 
prognosis. In the present case, in addition to enlarged hilar and 
mediastinal masses, the observation of elevated serum NSE 
levels and positive immunohistochemical staining of neuro-
endocrine markers, including chromogranin A, suggested 
a diagnosis of SCLC. However, the poor patient response to 
platinum-containing chemotherapy did not correspond with 
SCLC. Autopsy findings demonstrated that the initial diagnosis 
of SCLC was incorrect. A large mass presenting with elevated 
serum NSE and small atypical cells with a high N/C ratio had 
been obtained during a bronchoscopy and suggested that a 
primary SCLC lesion may be located adjacent to the medias-
tinum, forming a large mass with the metastatic mediastinal 
lymph nodes. Metastases to the lungs, pleura and mediastinal 
lymph nodes from primary RCC lesions are not rare; however, 
renal metastasis from a primary SCLC lesion is rare (18).
The prognosis of patients with metastatic RCC remains 
poor, since a key prognostic factor in RCC is the clinical 
stage of the disease (19). Several targeted therapy drugs, such 
as sunitinib, sorafenib, bevacizumab and temsirolimus, have 
been approved for use in patients with RCC (20). However, 
in addition to cytotoxic drugs, molecular targeting agents, 
including mammalian target of rapamycin inhibitors and tyro-
sine kinase receptors, have recently been introduced for the 
treatment of patients with RCC, and a survival benefit has been 
demonstrated in certain clinical trials (21,22).
In conclusion, despite the occurrence of RCC being rare, it 
should be considered in the differential diagnosis, particularly 
when a mass located in the kidneys presents with metastases to 
the mediastinal lymph nodes and elevated NSE serum levels, 
even if there is no involvement of the abdominal lymph nodes 
and the primary lesion is of a small size.
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